SAN DIEGO--(BUSINESS WIRE)--Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH), the world leader in the development of a new class of small molecule compounds based on endogenous steroid hormones, today reported on the Company’s progress in its drug development programs for metabolic disorders, inflammatory diseases and cancer, and announced financial results for the third quarter of 2008.
